Advances in Therapy is an international, open choice, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad, covering the use of therapies, devices, and surgical techniques across all therapy areas. The key features of the journal are:
Rapid publication: The journal aims for a 2-week peer review, 3-4 weeks from acceptance to online.
Open access option: The journal offers an open access option for all articles submitted to the journal. If you choose open access publication you will be required to pay an additional fee of €3060/ $3860/ £2560 upon acceptance of your article.
Inclusivity: All scientifically sound research considered be it positive, confirmatory or negative data. Research is considered from clinical phase, real-world and health economics outcomes studies. Submissions are welcomed whether they relate to an international or a country-specific audience.
Personal service: The journal’s team will re-format articles and upload submissions on behalf of authors, if necessary.
Digital Features and Plain Language Summaries: These peer-reviewed features are welcomed to help enhance the educational value of a manuscript (for more information see “Author Information – Guidelines for digital features and plain language summaries” under “Submission guidelines”).
Publication fees: Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €6250/ $7100 / £5100. The journal will consider fee discounts and waivers for developing countries and this is decided on a case by case basis.
- Publishing model
- Hybrid. Learn about publishing Open Access with us
- 3.871 (2019)
- Impact factor
- 3.558 (2019)
- Five year impact factor
- 16 days
- Submission to first decision
- 51 days
- Submission to acceptance
- 936,473 (2020)
Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists
Authors (first, second and last of 4)
Resuscitative Effect of Centhaquine (Lyfaquin®) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial
Authors (first, second and last of 11)
Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1
Authors (first, second and last of 6)
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
Authors (first, second and last of 12)
About this journal
- Print ISSN
- Abstracted and indexed in
- BFI List
- Biological Abstracts
- CAB Abstracts
- Chemical Abstracts Service (CAS)
- Current Contents/Clinical Medicine
- EBSCO Biomedical Reference Collection
- EBSCO CINAHL
- EBSCO Discovery Service
- Google Scholar
- INIS Atomindex
- Institute of Scientific and Technical Information of China
- Japanese Science and Technology Agency (JST)
- Journal Citation Reports/Science Edition
- OCLC WorldCat Discovery Service
- ProQuest-ExLibris Primo
- ProQuest-ExLibris Summon
- Science Citation Index Expanded (SciSearch)
- Semantic Scholar
- TD Net Discovery Service
- UGC-CARE List (India)